NCT04108208 2026-03-16
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
Clinical Trials
35 trialsNCT05348876 2026-01-30
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Bayer
Phase 4 Recruiting
NCT04373564 2026-01-22
ODYSSEY
Guerbet
Phase 4 Recruiting
NCT06074510 2025-09-11
MIRROR
Lantheus Medical Imaging
Phase 4 Active not recruiting
NCT06604442 2025-09-11
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics
Phase 4 Completed
NCT05803941 2025-04-24
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
Phase 4 Recruiting
NCT02918968 2024-12-09
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Astellas Pharma Inc
Phase 4 Completed
NCT03035032 2024-11-26
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Astellas Pharma Inc
Phase 4 Completed
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT00953277 2024-08-12
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
Axogen Corporation
Phase 4 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT05304169 2022-03-31
PRIZE
Zodiac Produtos Farmaceuticos S.A.
Phase 4 Completed
NCT02726009 2021-12-15
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
Ferring Pharmaceuticals
Phase 4 Completed
NCT01753297 2020-12-09
PRIORITI
Ipsen
Phase 4 Completed
NCT02441517 2018-04-19
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
Astellas Pharma Inc
Phase 4 Terminated
NCT00219271 2017-05-31
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Novartis
Phase 4 Completed
NCT01933022 2017-03-09
EFFECT
Astellas Pharma Inc
Phase 4 Terminated
NCT00470834 2017-02-27
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
GlaxoSmithKline
Phase 4 Completed
NCT00237146 2017-02-23
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Novartis
Phase 4 Completed
NCT00242554 2017-02-23
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Novartis
Phase 4 Completed
NCT00434317 2017-02-23
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00334139 2017-02-07
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Novartis
Phase 4 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT00375765 2017-01-19
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
GlaxoSmithKline
Phase 4 Completed
NCT00391690 2016-11-18
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Novartis
Phase 4 Completed
NCT01083199 2016-04-12
Global Performance Evaluation of the AMS CONTINUUM™ Device
American Medical Systems
Phase 4 Completed
NCT01511874 2015-09-23
Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
HanAll BioPharma Co., Ltd.
Phase 4 Completed
NCT01950871 2015-01-05
PHSTT-01
Advanced Medical Diagnostics s.a.
Phase 4 Terminated
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed
NCT00172016 2012-04-30
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Novartis
Phase 4 Completed
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00280098 2009-12-07
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT00035997 2009-11-23
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Novartis
Phase 4 Completed
NCT00590213 2008-01-25
COMART
AstraZeneca
Phase 4 Completed
NCT00103623 2006-09-19
The Plenaxis® Experience Study
PRAECIS Pharmaceuticals Inc.
Phase 4 Suspended